Repligen (RGEN) Tops Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
February 17, 2022 7:30 AM ESTRecord revenue of $186.5 million for the quarter, and year-over-year growth of 72%
Record revenue of $670.5 million for the year, and year-over-year growth of 83%
Organic revenue growth of 69% for the fourth quarter and 71% for the year 2021
Completes acquisition of single-use fluid management component manufacturer BioFlex Solutions
WALTHAM, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2021. Provided in this press release are... More
